Document is current
Any future updates will be listed below
-
Authors
Wang, Yulei
Lu, Li-Chun https://orcid.org/0000-0001-8975-9491
Guan, Yinghui
Ho, Ming-Chih
Lu, Shan
Spahn, Jessica
Hsu, Chih-Hung
-
Funding
Funding for this research was provided by:
Ministry of Science and Technology, Taiwan (MOST 108-2314-B-002-076-MY3, MOST 108-2314-B-002-073, MOST 109-2314-B-002-225)
- License Information
-
More Information
Article History
Received: 19 May 2021
Accepted: 3 August 2021
First Online: 16 August 2021
Declarations
:
: This study was approved by the Research Ethics Committee of National Taiwan University Hospital. Written informed consent was obtained from the patient involved in the study.
: Written informed consent was obtained from the patient involved in the study.
: Wang Y, Guan Y, Lu S and Spahn J are employees of Genentech, Inc., and shareholders of Roche. Lu LC received honorarium from Eli Lilly, Bristol-Meyers Squibb, Ono Pharmaceutical, and Roche. Hsu CH served as an advisory or consulting role for Eli Lilly, Genentech, Roche, Bristol-Meyers Squibb, Ono Pharmaceutical, Merck Sharp & Dohme, and Merck Serono; Hsu CH received honorarium from Bristol-Meyers Squibb, Ono Pharmaceutical, Merck Sharp & Dohme, and Roche; and Hsu CH received research funding from AstraZeneca, BeiGene, Bristol Myers Squibb, Ono Pharmaceutical, Genentech, Roche, and Merck Sharp & Dohme.
